For the Inventor, By the Inventor

Enter assignee name

Montreal, Canada

Theratechnologies Inc.

USPTO Granted Patents = 29

CIPO Patents = 2

EPO Patents = 2

Trademarks = 6

Forward Citations = 1,469

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Krishna G Peri (10 out of 16 patents)

Paul Brazeau (9 out of 15 patents)

Denis Gravel (8 out of 15 patents)

4. Thierry Abribat (6 out of 8 patents)

5. Abdelkrim Habi (6 out of 10 patents)

6. Soraya Allas (5 out of 5 patents)

7. Andre De Villers (4 out of 4 patents)

8. Alcide Chapdelaine (4 out of 4 patents)

9. Daniel Abran (4 out of 4 patents)

10. Thierry Abribat (4 out of 6 patents)

11. Michel Ibea (4 out of 4 patents)

12. Serge Moffett (3 out of 9 patents)

13. Sylvain Chemtob (2 out of 13 patents)

14. Felix Polyak (2 out of 2 patents)

15. Eryk Thouin (2 out of 3 patents)

29 patents: Sort by Forward Citations

1. 9334314 - Peptide compounds derived from melanotransferrin and uses thereof (2016-05-10),

2. 9073963 - [object Object] (2015-07-07),

3. 8871713 - Formulations of growth hormone releasing factor (GRF) molecules with improved stability (2014-10-28),

4. 8822413 - Bifunctional hormone having alpha-MSH activity and natriuretic peptide activity and uses thereof (2014-09-02),

5. 8481489 - GH secretagogues and uses thereof (2013-07-09),

6. 8435945 - GH secretagogues and uses thereof (2013-05-07),

7. 8361964 - Growth hormone releasing factor (GRF) analogs and uses thereof (2013-01-29),

8. 8314066 - GH secretagogues and uses thereof (2012-11-20),

9. 7893025 - Use of growth hormone releasing factor analogs in treating patients suffering from wasting (2011-02-22),

10. 7538185 - Glucagon-like peptide-1 analogs with long duration of action (2009-05-26),

11. 7521530 - [object Object] (2009-04-21),

12. 7414029 - Antagonistic peptides of prostaglandin E2 receptor subtype EP4 (2008-08-19),

13. 7316997 - GH secretagogues and uses thereof (2008-01-08),

14. 7094761 - Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions (2006-08-22),

15. 7067488 - Modified GLP-1 peptides with increased biological potency (2006-06-27),

THERATECHNOLOGIES INC. is a leading biotechnology company that develops and commercializes innovative therapies for various diseases. With a focus on innovative research, they aim to provide novel solutions to improve patients' quality of life. The company offers a wide range of products within the fields of endocrinology and oncology. Headquartered in Canada, THERATECHNOLOGIES INC. operates globally, collaborating with healthcare professionals and industry partners to bring groundbreaking treatments to those in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

29 Patents

#33 in Montreal

#453 in Canada

#21,856 in the World

Montreal, Canada

Theratechnologies Inc.

Forward Citations = 1,469

40 inventors:

Krishna G Peri (10 out of 16 patents)

Paul Brazeau (9 out of 15 patents)

Denis Gravel (8 out of 15 patents)

4. Thierry Abribat (6 out of 8 patents)

5. Abdelkrim Habi (6 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…